Pliant Therapeutics Inc.

Pliant Therapeutics Inc. is a biotechnology firm engaged in the development of novel therapeutics aimed at treating fibrosis. Its core mission is to discover and create medicines targeting integrin proteins, which play a critical role in fibrosis, a condition where the body produces excessive connective tissue due to injury or disease. By focusing on integrin targets, Pliant Therapeutics aims to disrupt fibrotic processes at their biological core, potentially addressing chronic and life-threatening fibrotic diseases across various organ systems. Pliant's portfolio primarily addresses fibrotic conditions in the lungs and liver, with potential applications in other fibrotic manifestations. The firm's approach combines biology, chemistry, and biomolecular engineering, positioning it at the forefront of precision therapies in fibrosis management. Within the pharmaceutical and healthcare sectors, Pliant Therapeutics holds significant promise due to its cutting-edge research and specialized focus on unsolved medical needs. The company, headquartered in the United States, contributes to the broader biopharmaceutical landscape by offering innovative treatment avenues and enhancing the quality of life for patients afflicted with severe fibrotic conditions.